TCD601 for Kidney
Study Summary
This trial will test how well a new drug works in combination with bone marrow cells from a donor to help prevent organ rejection in people who have recently received a kidney transplant.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: 24 months
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Arm 1
1 of 3
Arm 2
1 of 3
Arm 3
1 of 3
Experimental Treatment
18 Total Participants · 3 Treatment Groups
Primary Treatment: TCD601 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 65 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 16th, 2021
Last Reviewed: November 30th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.